Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy

BACKGROUND: Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease than aspirin alone. OBJECTIVE: This analysis aimed to economically compare the cost effectiveness of rivaroxaban (2....

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrara, Pietro, Cortesi, Paolo A., Di Laura, Danilo, Maggioni, Aldo P., Mantovani, Lorenzo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149345/
https://www.ncbi.nlm.nih.gov/pubmed/33725323
http://dx.doi.org/10.1007/s40261-021-01023-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149345/
https://www.ncbi.nlm.nih.gov/pubmed/33725323
http://dx.doi.org/10.1007/s40261-021-01023-8

Ejemplares similares